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Cancer serumProhaptoglobin (proHp) is processed into mature haptoglobin via site-speciﬁc cleavage. Although
haptoglobin has been well studied, the functions of proHp remain unclear. We investigated the
angiogenic action of proHp in endothelial cells, demonstrating that proHp upregulated vascular
endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR2) expression and endothelial
sprouting and branching. ProHp-induced sprouting was attenuated by a VEGFR2 inhibitor.
Moreover, proHp was detected in sera of cancer patients by immunoprecipitation and Western blot.
These ﬁndings indicate that proHp promotes angiogenesis via VEGF/VEGFR2 signalling, and serum
proHp level may be a useful biomarker for diseases associated with angiogenesis.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Haptoglobin (Hp) is an acute phase plasma protein [1–3] that
can act either as an anti-inﬂammatory modulator or a pro-in-
ﬂammatory activator during an inﬂammatory response [4–7]. In
addition, Hp appears to be involved in arterial restructuring and
vascular disease [8–10]. Hp protein consists of two chains, the a-
chain and the b-chain, but is synthesised from a single mRNA.
After synthesis of the polypeptide pre-prohaptoglobin, which con-
tains a signal peptide and the a- and b-subunits, prohaptoglobin(proHp) is generated by removal of the N-terminal signal peptide.
In the endoplasmic reticulum, proHp is speciﬁcally cleaved at the
a–b junction site by a serine protease, separating the a- and b-
chains [11,12]. In mature Hp, the separated a- and b-chains are
connected by disulphide bonds, and eventually form a tetramer
or polymer [13–15]. Although most Hp is released into circulation
as mature protein, considerable amounts of proHp are also
secreted [11,12]. However, the biological signiﬁcance of proHp
secretion and its function(s) remain largely unknown.
Complement C1r-like protein (C1r-LP), a serum protein of hep-
atic origin containing the serine protease domain of C1r, has been
identiﬁed as a speciﬁc proHp-cleaving enzyme [16]. Although Hp is
synthesised mainly in the liver, which is also a major site of C1r-LP
synthesis, non-hepatic Hp expression has been observed in the
arteries, lung, adipose tissue, and leukocytes [17–21]. ProHp may
be secreted from non-hepatic cells lacking C1r-LP or under patho-
logical conditions in which C1r-LP activity is suppressed.
Recently we found that endothelial progenitor cells (EPCs)
transfected with the gene encoding Hp exhibit improved angio-
genic/vasculogenic potential and greater ability to restore blood
perfusion in a mouse model of hindlimb ischemia [22]. However,
in that study it was not identiﬁed which Hp isoformwas expressed.
Since the proHp-processing enzyme C1r-LP is primarily expressed
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precursor form of Hp (proHp), which contributed to angiogenesis.
Therefore, in the present study we evaluated the angiogenic action
of proHp and its presence in the serum of patients with liver cancer
and healthy individuals.
2. Materials and methods
2.1. Plasmid constructs and site-directed mutagenesis
The open reading frame of human Hp2 cDNA [18] was sub-
cloned into the EcoRI and KpnI sites of the pcDNA3.0 vector con-
taining a C-terminal FLAG gene (gift from H.S. Rhim at The
Catholic University of Korea, Seoul, Korea). To replace arginine
(CGG) with glutamine (CAG) at amino acid 143 (R143Q) in
proHp2, a single point mutation in the Hp2 gene was generated
using an oligonucleotide QuikChange site-directed mutagenesis
kit (Stratagene, La Jolla, CA) according to the manufacturer’s
instructions. The speciﬁc mutation was conﬁrmed by DNA
sequencing (Macrogen Inc., Seoul, Korea). Hereafter, Hp2 and
proHp2 will be referred to as Hp and proHp, respectively.Fig. 1. Secretion of proHp from Hp-transfected COS-7 cells. (A) Structural difference b
precursor protein, and mature Hp consists of a- and b-chains, which are generated by cle
electrophoresed on a 12% SDS–polyacrylamide gel under reducing conditions, and Hp w
were stably transfected with empty vector or vector expressing human Hp cDNA. After c
collected, and the presence of proHp in the CM was veriﬁed by Western blot using the2.2. Cell culture and conditioned medium collection
Human umbilical vein endothelial cells (HUVECs) were isolated
from fresh umbilical veins, as previously described [22,23]. The
cells were cultured in endothelial growth medium (EGM-2 Bullet
Kit™ medium; Clonetics, San Diego, CA) supplemented with 5%
FBS (Gibco Laboratories, Gaithersburg, MD) and used at passages
3 through 7. COS-7 cells were maintained in DMEM (JBI
WelGENE, Daegu, Korea) supplemented with 10% FBS.
To generate proHp-overexpressing cells, COS-7 cells were trans-
fected with plasmid DNA containing the wild type or mutant Hp
gene using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Stably
transfected COS-7 cells were then selected by exposure to 1 mg/
ml G418 (Invitrogen). For knockdown of Hp gene expression, small
interfering RNA (siRNA; Dharmacon Inc., Lafayette, CO) against Hp
was introduced into stably Hp-transfected COS-7 cells using
DharmaFECT 4 reagent (Dharmacon), according to the manufac-
turer’s protocol.
For conditioned medium (CM) collection, Hp-transfected COS-7
cells were grown to approximately 80% conﬂuency in 150-mm cul-
ture dishes. The culture medium was then replaced with freshetween proHp and Hp isoforms is schematically shown. ProHp is the single-chain
avage at Arg143 of proHp. ⁄Glycosylation site. (B) Normal human serum (0.2 ll) was
as detected with antibodies against Hp, Hp a-chain, and Hp b-chain. (C) COS-7 cells
ells were cultured for 48 h in serum-free DMEM, the conditioned medium (CM) was
same antibodies.
Fig. 2. Effects of proHp-containing CM on VEGF/VEGFR2 expression and tube formation in HUVECs. (A) HUVECs were incubated in EGM-2 medium supplemented with 5% FBS
and CM containing 0.2 lg/ml proHp or control CM from cells transfected with empty vector. After a 24-h incubation, mRNA levels of VEGF and VEGFR2 in the treated cells
were determined by qRT-PCR and normalised to GAPDH. (B) HUVECs were incubated for 24 h in 1% FBS-supplemented EBM-2 medium containing CM containing 0.2 lg/ml
proHp or control CM, and secreted VEGF was measured by ELISA. VEGF level was expressed as pg VEGF per lg cellular protein. (C) HUVECs were cultured in medium
containing either CM containing 0.2 lg/ml proHp or control CM. After 24 h, the cells were stained with allophycocyanin-conjugated VEGFR2 antibody and analysed by ﬂow
cytometry. (D) HUVECs were plated on growth factor-reduced Matrigel and treated with CM containing 0.2 lg/ml proHp or control CM. After a 6-h incubation, capillary-like
tube formation was observed (scale bar = 100 lm), and total tube branch lengths in three random ﬁelds were measured. Results are expressed as mean ± S.D. of triplicate
experiments. ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001 vs. control CM-treated cells (A, B, D). Data shown in (C) and (D) are representative of independent experiments performed at least twice.
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and concentrated 10-fold using a centrifugal ﬁlter device
(Amicon ultra-30kDa; Millipore, Bedford, MA). The CM was used
after ﬁltration through a 0.22-lm Spin-X centrifuge tube ﬁlter
(Costar, Corning, NY).
2.3. Puriﬁcation of proHp(Gln)
CM was collected from 48-h cultures of COS-7 cells that stably
expressed the FLAG-tagged proHp protein (R143Q). The CM was
concentrated, mixed with an equal volume of Tris-buffered saline,
and loaded onto the Anti-FLAG M2 afﬁnity gel (Sigma–Aldrich, St.
Louis, MO). After washing the gel, bound protein was eluted with
100 lg/ml FLAG peptide (Sigma–Aldrich) and dialysed against
PBS using a Spectra/Por dialysis membrane (Spectrum
Laboratories, Rancho Dominguez, CA).2.4. Sandwich enzyme-linked immunosorbent assay (ELISA)
To determine proHp concentration, ELISA was performed using
puriﬁed human Hp (2-2 type, Sigma–Aldrich) as a standard. The
ELISA plates (Nunc, Roskilde, Denmark) were coated with 10 lg
anti-human Hp antibody (Sigma–Aldrich) in 100 ll PBS by over-
night incubation at 4 C. After washing the plates and blocking
with 3% skim milk, samples were added to the wells containing
immobilised antibodies and incubated for 2 h at room tempera-
ture. Captured proHp was incubated with anti-human Hp sec-
ondary antibody conjugated to horseradish peroxidase (Abcam,
Cambridge, UK). The assay was developed with tetramethylben-
zidine substrate solution (GenDEPOT, Barker, TX), and the colour
reaction was stopped by adding 2 M H2SO4. Absorbance was mea-
sured at 450 nm using the Victor3 ELISA reader (PerkinElmer,
Boston, MA).
Fig. 3. Angiogenic function of proHp. COS-7 cells stably expressing proHp were transfected with siRNA against Hp or control siRNA. (A) Inhibition of proHp expression by Hp
siRNA was conﬁrmed by Western blot. (B) HUVECs were treated for 24 h with CM from cells transfected with control siRNA (0.2 lg/ml proHp) or CM from cells transfected
with Hp siRNA (0.03 lg/ml proHp). Expression levels of VEGF and VEGFR2 were determined by qRT-PCR and normalised to GAPDH. Results are expressed as mean ± S.D. of
triplicate experiments. ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001 vs. control siRNA-transfected cells. (C) HUVECs on Matrigel were incubated for 6 h with similar volumes of CM obtained from
cells treated with control siRNA (0.2 lg/ml proHp) or cells treated with Hp siRNA (0.03 lg/ml proHp). The formation of a tubular network was observed, and total tube
lengths in three random ﬁelds were measured.
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Systems, Minneapolis, MN) according to the manufacturer’s
instructions and normalised to protein content (Bio-Rad,
Hercules, CA).
2.5. Western blot analysis
COS-7 CM and serum proteins were separated on a 10% SDS–
polyacrylamide gel, and Hp isoforms were identiﬁed using anti-hu-
man Hp antibody (Sigma–Aldrich) and polyclonal antibodies
against human Hp a-chain and Hp b-chain, which were prepared
from rabbit sera after immunization against the corresponding
recombinant protein [24]. The immunoreactive proteins were
detected using an enhanced chemiluminescence detection kit
(Amersham Biosciences, Buckinghamshire, UK) and luminescent
image analysis LAS-3000 system (Fujiﬁlm, Tokyo, Japan).
2.6. Flow cytometric analysis
To detect the VEGF receptor (VEGFR) on the surface of HUVECs,
direct immunoﬂuorescence staining was performed. Brieﬂy,
proHp-treated HUVECs (1  106 cells) were incubated at room
temperature for 30 min with allophycocyanin-conjugated anti-hu-
man VEGFR2 mouse monoclonal antibody (R&D Systems). The
incubated cells were washed and resuspended in 1% FBS solution.
Cytometric analysis was carried out using a FACSCanto II ﬂow
cytometer (BD Biosciences, San Diego, CA).2.7. Quantitative reverse-transcription PCR (qRT-PCR)
Total RNAwas isolated fromtheHUVECs and reverse-transcribed
into cDNA. Quantitative PCR (qPCR) was performed in a Mx3000P
thermal cycler (Stratagene) using the SYBR Premix Ex Taq™ kit
(TaKaRa, Otsu, Japan) and the following gene-speciﬁc primers:
VEGF-A, 50-GCGGAGAAAGCATTTGTTTGT-30 (forward) and 50-
TTGCAGATGTGACAAGCCG-30 (reverse); VEGFR2, 50-TGGGAACC
GGAACCTCACTATC-30 (forward) and 50-GTCTTTTCCTGGGCACC
TTCTATT-30 (reverse); GAPDH, 50-ACCACAGTCCA TGCCATCAC-30
(forward) and 50-TCCACCACCCTGTTGCTGTA-30 (reverse)
2.8. In vitro tube formation on Matrigel and cell migration assay
Cold growth factor-reduced Matrigel (BD Biosciences) was poly-
merised in each well of a 48-well plate by incubating at 37 C for
30 min. HUVECs (4  104 cells/well) suspended in 0.5% FBS-supple-
mented endothelial basal medium (EBM-2; Clonetics, San Diego,
CA) were plated on the Matrigel. The cells were treated with
proHp and incubated for 6 h. Tubular network formation was
observed microscopically and photographed. The degree of tube
formation was quantiﬁed by measuring the length of the tubes in
three random ﬁelds and calculating distances with ImageJ software
(National Institutes of Health).
Cell migration was analysed using the Oris™ cell migration
assay kit (Platypus Technologies LLC, Madison, WI) according to
the manufacturer’s instructions.
Fig. 4. Preparation of proHp(Gln). (A) Schematic structure of proHp(Gln) in which 143-arginine of proHp is substituted with glutamine. ⁄Glycosylation site. (B and C) COS-7
cells were stably transfected with single point-mutated Hp gene, and proHp(Gln) was isolated from the CM. The puriﬁed proHp(Gln) was veriﬁed by silver staining (B) and
Western blot analysis (C). Human Hp puriﬁed from normal serum was also analysed for comparison.
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An aortic ring assay to assess ex vivo angiogenesis was per-
formed with aortic rings obtained from 8-week-old C57BL/6 mice
(Orient, Sungnam, Korea) using the method described by Baker
et al. [25]. Brieﬂy, extraneous fat and branching vessels were
removed from harvested aortas, and blood was ﬂushed from the
lumen. The aortas were then cut into 1-mm thick rings and incu-
bated overnight at 37 C in Opti-MEM (Gibco Laboratories). The
next day the aortic rings were embedded in growth factor-reduced
Matrigel in each well of a 96-well plate and incubated in 0.5% FBS-
supplemented EBM-2 medium containing proHp(Gln). For the
VEGFR2 inhibition experiment, the aortas were pre-treated with
50 nM SU5416 (Calbiochem, San Diego, CA). The medium was
changed every 3 or 4 days. On day 7, sprouting vessels were
observed microscopically and photographed at 100 magniﬁca-
tion. All animal procedures were approved by the Ethics
Committee of the Catholic University of Korea.
2.10. Immunoprecipitation
Serum specimens (5 ll each) from cancer patients and healthy
subjects were mixed with antibody against the Hp b-chain and
incubated for 4 h at 4 C with gentle shaking. Protein G-conjugated
agarose beads (Invitrogen) were added, and the mixture was incu-
bated overnight at 4 C. After centrifugation, the supernatant was
removed, and the precipitated immune complex was washed threetimes with cold PBS. The immune complex was electrophoresed on
a 10% SDS–polyacrylamide gel and analysed by Western blot using
antibody against the Hp a-chain. Study protocols were approved
by the institutional review board of the Catholic University of
Korea, Incheon St. Mary’s Hospital.
2.11. Statistical analysis
Data were analysed by unpaired Student’s t-test using PASW
Statistics software (version 18; SPSS, Inc., Chicago, IL); P < 0.05
was considered signiﬁcant.
3. Results
3.1. Preparation of COS-7 CM containing proHp
Single-chain proHp is converted to Hp by a proteolytic cleavage
at the a–b junction site and subsequent linking of the a- and b-
chains by disulphide bond (Fig. 1A). In the serum of healthy
individuals, Hp exists primarily as a polymer of a- and b-chains
through further disulphide linkages among the a-chains. After
electrophoresis under reducing conditions, Hp from normal serum
can be detected as two chains (a-chain and b-chain) by Western
blot (Fig. 1B).
When Hp cDNA was transfected into COS-7 cells, in which the
proHp-processing enzyme C1r-LP is deﬁcient [16], a single
polypeptide proHp was secreted into the cell culture medium.
Fig. 5. Potent angiogenic activity of proHp(Gln). (A) HUVECs were treated with 0.1 lg/ml proHp(Gln) for 24 h, and mRNA levels of VEGF and VEGFR2were determined by qRT-
PCR. (B) HUVECs were incubated in 1% FBS-supplemented EBM-2 medium containing 0.1 lg/ml proHp(Gln) for 24 h. VEGF secreted into the CM was measured by ELISA. (C)
After 24-h culture of HUVECs in the presence of 0.1 lg/ml proHp(Gln), VEGFR2 expression was analysed by ﬂow cytometry. (D) Capillary-like tube formation by HUVECs
treated with proHp(Gln) was observed after 6 h, and the total tube lengths were measured in three randomly chosen ﬁelds. (E) HUVECs were seeded on collagen I-coated
wells and cultured for 24 h. When the cells were conﬂuent, the silicone stopper was removed. The remaining cells were further incubated in the presence of 0.1 lg/ml
proHp(Gln). After the 24-h incubation, cell migration was measured at 12 random sites (scale bar = 100 lm). Data shown in (A–E) are representative of independent
experiments performed in duplicate. ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001 vs. PBS-treated control. (F) Mouse aortic rings were embedded in growth factor-reduced Matrigel and
preincubated for 40 min in 0.5% FBS-supplemented EBM-2 medium with or without the VEGFR2 inhibitor SU5416 (50 nM). The embedded rings were then treated with
0.1 lg/ml proHp(Gln). After 7 days, sprouting vessels were observed (scale bar = 100 lm). The number of sprouts is expressed as mean ± S.D. of data from seven aortic rings.
⁄⁄⁄P < 0.001 vs. PBS-treated control. ###P < 0.001 vs. proHp(Gln)-treated group in the absence of inhibitor SU5416.
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polypeptide reacted with speciﬁc antibodies against both Hp
a-chain and Hp b-chain (Fig. 1C). These ﬁndings indicate that the
precursor proHp rather than the mature Hp protein is produced
in Hp-transfected COS-7 cells. The CM of the Hp-transfected
COS-7 cells was used as the source of proHp in this study.3.2. Effect of exogenous proHp on angiogenesis in HUVECs
After the concentration of proHp in the CM was determined by
ELISA, HUVECs were incubated with CM from Hp-transfected COS-
7 cells (ﬁnal proHp concentration of 0.2 lg/ml). HUVECs incubated
with CM from vector-transfected COS-7 cells served as a control.
Fig. 6. Detection of proHp in sera of patients with hepatoma. (A) Serum specimens (5 ll) from patients with liver cancer or healthy controls were immunoprecipitated with
anti-Hp b-chain antibody, and the precipitated complexes were analysed by Western blot using an anti-Hp a-chain antibody. Relative band intensity is expressed in arbitrary
units. In each serum specimen, total Hp and total protein levels were determined by ELISA and the Bradford method, respectively. (B) The band intensity of proHp and
concentrations of total Hp and total protein in serum specimens of patients with liver cancer were compared with those of healthy controls. Horizontal lines indicate mean
values. ⁄⁄P < 0.01 vs. healthy controls.
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VEGFR2 mRNA and protein levels in cells treated with CM contain-
ing proHp (proHp CM) compared to the control (Fig. 2A–C). Tube
formation on Matrigel was also enhanced in proHp CM-treated
HUVECs (Fig. 2D). To conﬁrm that the angiogenic effect of proHp
CM was due to proHp itself, Hp-transfected COS-7 cells were trans-
fected with Hp-speciﬁc siRNA (Fig. 3A). HUVECs treated with CM
from the proHp-knockdown cells showed signiﬁcantly decreased
VEGF/VEGFR2 expression and in vitro tube formation compared
with cells transfected with control siRNA (Fig. 3B and C), suggest-
ing that proHp induced angiogenesis. Taken together, these ﬁnd-
ings indicate that proHp exhibits potent angiogenic activity.
3.3. Single point mutation of Hp gene and preparation of proHp(Gln)
To conﬁrm that proHp acts as an angiogenic factor, we
attempted to isolate proHp from COS-7 CM; however, we failed
to isolate intact proHp because cleavage occurred during puriﬁca-
tion. Therefore, we introduced a single point mutation in the a–b
junction cleavage site of Hp, substituting guanine (CGG) with ade-
nine (CAG) in codon 143, thereby replacing arginine with glu-
tamine in the protein (Fig. 4A). COS-7 cells were transfected with
the mutated Hp gene, and proHp(Gln) was puriﬁed from the
COS-7 CM. Silver staining of the isolated protein showed a major
band of 68kDa and a few minor bands (Fig. 4B). Western blot
analysis identiﬁed the major band as proHp containing both a-
and b-chains (Fig. 4C).
3.4. Potent angiogenic activity of proHp(Gln)
Treatment of HUVECs with 0.1 lg/ml puriﬁed proHp(Gln)
increased both mRNA and protein levels of VEGF and VEGFR2(Fig. 5A–C). ProHp(Gln) also increased tube formation on
Matrigel and cell migration (Fig. 5D and E). Another mutant
proHp (R143L, proHp[Leu]) produced similar angiogenic effects in
HUVECs (data not shown). Ex vivo angiogenesis was evaluated
using the mouse aortic ring assay (Fig. 5F). When the aortas
embedded in Matrigel were treated with 0.1 lg/ml proHp(Gln),
microvessel sprouting was markedly increased. However, this
effect was diminished by pre-treatment with the VEGFR2 inhibitor
SU5416 (Fig. 5F), suggesting that proHp promotes angiogenesis in
HUVECs via VEGF/VEGFR2 signalling.
3.5. Detection of proHp in the sera of cancer patients
To verify the presence of proHp in the circulation of patients
with cancer, we analysed the sera of eight patients with liver can-
cer. Results of immunoprecipitation and Western blotting revealed
the presence of proHp in sera from six of the eight patients,
whereas little or no proHp was detected in normal human sera
(Fig. 6A). We also measured levels of total Hp (approximately equal
to mature Hp level) and total protein in the serum samples. The
mean total Hp level was higher in patients with hepatomas than
in healthy controls; however, this difference was not signiﬁcant.
Similarly, total protein levels did not differ signiﬁcantly between
groups (Fig. 6B). These ﬁndings suggest that the increase in serum
levels of proHp is disease-dependent.
4. Discussion
In human circulation, Hp protein exists primarily as the mature
isoform generated from its precursor proHp. Although circulating
Hp has been well studied, the functions of proHp remain unclear.
A few studies have described proHp as a human zonulin
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cell survival and differentiation [26,27]. In the current study, we
identiﬁed a novel angiogenic function of proHp and detected
proHp in the serum of patients with liver cancer.
Cid et al. isolated an angiogenic factor from sera of patients with
systemic vasculitis and identiﬁed the angiogenic protein as Hp
[28]. The authors also showed that Hp puriﬁed from normal human
plasma stimulated in vitro and in vivo Matrigel angiogenesis at
concentrations greater than 50 lg/ml and 1 mg/ml, respectively.
However, because human plasma contains 0.4 to 2 mg/ml Hp
under normal conditions [15], it seems unlikely that Hp in normal
plasma directly acts on endothelial cells. We hypothesised that an
unusual isoform of Hp with angiogenic functions might be pro-
duced under physiological or pathological conditions associated
with angiogenesis. Our results indicate that proHp displays potent
angiogenic activity. Speciﬁcally, proHp upregulated VEGF/VEGFR2
expression and tube formation on Matrigel at a low concentration
(0.2 lg/ml). Mutant proHp(Gln), which cannot convert to Hp, was
effective at a lower dose (0.1 lg/ml). In addition, proHp(Gln) pro-
moted endothelial sprouting and branching in the ex vivo mouse
aortic ring assay, and proHp-augmented sprouting was attenuated
by treatment with a VEGFR2 inhibitor. However, mature Hp puri-
ﬁed from normal human serum did not exert angiogenic effects,
even at the concentration of 2 lg/ml (data not shown). In a pre-
vious study, we demonstrated that the angiogenic and vasculo-
genic effects of EPCs were improved by Hp transfection [22].
Although the speciﬁc Hp isoform involved in vascularization was
not identiﬁed in that study, we now propose that proHp con-
tributed to the improved function of the EPCs, based on the current
observation that Hp-transfected endothelial cells secrete proHp
but not the mature Hp isoform (data not shown). Further research
is needed to verify whether proHp or Hp is the active isoform dur-
ing angiogenesis.
Proteomic studies have suggested the usefulness of Hp as a
novel biomarker for cancer and inﬂammatory diseases, based on
changes in the protein’s glycosylation patterns and increased levels
in patients with these conditions [29–32]. However, because the
serum level of mature Hp varies considerably among individuals
[15], Hp level is not useful as a disease biomarker. Our data also
revealed considerable differences in total Hp levels among serum
samples. However, proHp may be a potential cancer biomarker,
as it was readily detected in the sera of hepatoma patients but
was found at very low levels in normal sera. Taken together, our
ﬁndings demonstrate that the proHp isoform is a more useful bio-
marker candidate.
Although we have identiﬁed proHp as a useful biomarker for
hepatoma, our sample size was small. Therefore, future studies
are needed to characterise the relationship between serum
proHp levels and disease progression using larger cohorts of
patients with cancer and healthy controls.
Hp has been considered an antioxidant and anti-inﬂammatory
mediator. However, its role as a pro-inﬂammatory factor and
immune response mediator has been also suggested [6,7,27].
These conﬂicting ﬁndings may be due to the diverse functions of
Hp isoforms produced in various cellular environments. In fact,
we recently identiﬁed a speciﬁc Hp fragment in the synovial ﬂuid
of patients with rheumatoid arthritis that appears to be produced
by plasmin and induces IL-6 expression [24]. Because of different
processing and post-translational modiﬁcations, such as glycosyla-
tion and protease cleavage, diverse Hp isoforms may be generated
in vivo. Therefore, identiﬁcation of the Hp isoform participating in
speciﬁc functions is needed to fully understand the physiological
and pathological roles of Hp.
In humans, two major Hp alleles (Hp1 and Hp2) have been iden-
tiﬁed and are expressed as three Hp phenotypes: homozygotes
Hp1-1 (Hp1/Hp1) and Hp2-2 (Hp2/Hp2) and heterozygote Hp2-1(Hp1/Hp2) [15,33]. The allelic polymorphism of Hp affects its func-
tional properties. Individuals with the Hp2-2 phenotype have a
greater risk of developing diabetic vascular complications and
renal disease [1,10,34,35]. In this paper we examined the effect
of proHp2 produced by Hp2 transfection. Further research is
needed to compare the angiogenic potential of proHp1 and
proHp2.
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